SCHEMBL22070053

SCHEMBL22070053

CCn1ncc2ccc3cnc([S+](C)[O-])nc3c21

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
HASPIN Q8TF76 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22070043 0.78
SCHEMBL29479924 0.76 DPP4 (0.34)
SCHEMBL22070046 0.76
SCHEMBL21670410 0.76 DPP4 (0.34)
SCHEMBL22070041 0.74 EZH2 (0.34)
SCHEMBL5264731 0.68 CDK4 (0.57)
SCHEMBL21670393 0.68 GSK3A (0.30)
SCHEMBL29479928 0.68 GSK3A (0.30)
SCHEMBL21670390 0.66 JAK1 (0.34)
SCHEMBL29479916 0.66 JAK1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993604-B2 Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) 2024-05-28 US disclosed
US-20220227775-A1 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) 2022-07-21 US disclosed
CN-111094291-B 1H-pyrazolo [4,3-H ] quinazoline compound as protein kinase inhibitor 晟科药业(江苏)有限公司 2022-06-21 CN disclosed
EP-3666774-B1 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) 2022-05-11 EP disclosed
EP-3666774-B1 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) 2022-05-11 EP disclosed
US-11319323-B2 Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) 2022-05-03 US disclosed
US-11319323-B2 Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) 2022-05-03 US disclosed
US-20210147424-A1 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) 2021-05-20 US disclosed
US-20210147424-A1 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) 2021-05-20 US disclosed
EP-3666774-A1 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) 2020-06-17 EP disclosed
CN-111094291-A 1H-pyrazolo [4,3-H ] quinazoline compound as protein kinase inhibitor 晟科药业(江苏)有限公司 2020-05-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993604-B2 Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors CDK1, CDK2, CDK3 HTR2A 3511/4885HTR2C 1782/4885HASPIN 834/4885
US-20220227775-A1 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR CDK1, CDKL1, CDK2 HTR2A 3204/4885HTR2C 1707/4885HASPIN 940/4885
US-20210147424-A1 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR CDK1, CDKL1, CDK2 HTR2A 3204/4885HTR2C 1707/4885HASPIN 940/4885
US-11319323-B2 Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors CDK1, CDK2, CDK3 HTR2A 3511/4885HTR2C 1782/4885HASPIN 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.